-
Mashup Score: 2
A pediatric patient with severe transplant-associated thrombotic microangiopathy responded to treatment with narsoplimab after experiencing disease progression on eculizumab.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The European Commission has expanded the current indication for avapritinib to include use as a single agent in adult patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, or mast cell leukemia, following at least 1 systemic treatment.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Avapritinib Approved in Europe for Advanced Systemic Mastocytosis #MPN #hemcsm https://t.co/tvUwaN6YKf
-
-
Mashup Score: 0
The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology has been revised to include ropeginterferon alfa-2b as a recommended treatment option for adult patients with polycythemia vera.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NCCN Recommends Ropeginterferon Alfa-2b in Clinical Practice Guidelines Update @mpdrc #MPN #hemcsm https://t.co/3yzEnWWN4Y
-
-
Mashup Score: 1
Zanubrutinib has been approved by the FDA for the treatment of patients with Waldenströms macroglobulinemia based on the results of the phase 3 ASPEN trial.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Zanubrutinib has been approved by the @US_FDA for the treatment of patients with Waldenströms macroglobulinemia based on the results of the phase 3 ASPEN trial. @FDAOncology #hemcsm https://t.co/ygVczq2EPK
-
-
Mashup Score: 0Lisaftoclax Shows Early Safety, Efficacy in Relapsed/Refractory CLL/SLL and Other Hematologic Cancers - 3 year(s) ago
The novel BCL-2 inhibitor lisaftoclax elicited encouraging responses with acceptable tolerability in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and other hematologic cancers.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Twelve of 15 evaluable patients with R/R CLL/SLL experienced a PR to treatment w/ lisaftoclax in the first-in-human phase 1 trial (NCT03537482), which translated to an ORR of 80% @MayoClinic @ASCO #ASCO21 #hemcsm https://t.co/WqFfjLC76O https://t.co/VtmbmAiVPY
-
-
Mashup Score: 1Luspatercept Achieves Impressive Hemoglobin Increase in Non-Transfusion–Dependent Beta-Thalassemia - 3 year(s) ago
Luspatercept-aamt achieved a 77.1% mean hemoglobin increase of 1.0 g/dL or higher from baseline over a continuous 12-week interval during weeks 13 to 24 in the absence of red blood cell transfusions vs 0% with placebo in patients with non-transfusion–dependent β-thalassemia.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Luspatercept-aamt achieved a 77.1% mean hemoglobin increase of 1.0 g/dL from baseline over a continuous 12-week interval in the absence of red blood cell transfusions vs 0% w/ placebo. @AliTaherMD @EHA_Hematology #EHA2021 #hemcsm https://t.co/dYd4eROrRy
-
-
Mashup Score: 0
For patients with myelofibrosis who have platelets counts of less than 50,000, pacritinib represents a potential therapeutic option that can fill a need that has been unmet with other approved JAK inhibitors, such as ruxolitinib and fedratinib.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Pacritinib represents a potential therapeutic option that can fill a need that has been unmet with other approved JAK inhibitors for patients with myelofibrosis who have platelets counts of less than 50,000. @AaronGerds @ClevelandClinic #MPN #hemcsm https://t.co/zQioA38Cle https://t.co/hsX7DwSZ9Q
-
-
Mashup Score: 0Pirtobrutinib Elicits Encouraging Efficacy in CLL, SLL, MCL, & Other Non-Hodgkin Lymphomas - 3 year(s) ago
Pirtobrutinib produced promising efficacy in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma, those with mantle cell lymphoma and other non-Hodgkin lymphomas, and those who progressed on Richter transformation–directed therapy.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Patients with previously treated CLL/SLL, those with MCL and other non-Hodgkin lymphomas, and those who progressed on Richter transformation–directed therapy, saw promising efficacy when using pirtobrutinib. #lymsm #leusm #hemcsm https://t.co/UIC0o4458s https://t.co/ym5TDrXfBg
-
-
Mashup Score: 0
For patients with myelofibrosis who have platelets counts of less than 50,000, pacritinib represents a potential therapeutic option that can fill a need that has been unmet with other approved JAK inhibitors, such as ruxolitinib and fedratinib.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
For patients with myelofibrosis who have platelets counts of less than 50,000, pacritinib represents a potential therapeutic option that can fill a need that has been unmet with other approved JAK inhibitors. @AaronGerds @ClevelandClinic #MPN #hemcsm https://t.co/SNKKyZjVKw
-
-
Mashup Score: 0Moving Curative Therapies Forward in Hematologic Malignancies - 3 year(s) ago
Because hematological cancers are rarer than solid tumors, information on treatment practices is somewhat less available, so hematologists are particularly interested in learning what their peers are doing.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Because hematological cancers are rarer than solid tumors, information on treatment practices is somewhat less available, so hematologists are particularly interested in learning what their peers are doing. @garciamanero @MDAndersonNews #hemcsm https://t.co/F3I2IkKI8y
-
Pediatric Patient With Severe TA-TMA Elicits Response to Narsoplimab @EmoryMedicine #hemcsm https://t.co/2q2CzgHO5y